EZR

Ezrin · P15311 · EZR on Sugi Atlas →

0 patent compounds predicted against EZR, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to EZR by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer PHASE2COMPLETED
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula PHASE2COMPLETED
TORI 104 Pre-Surgical Dasatinib PHASE2WITHDRAWN
Can E-cadherin Found in Tissue/Blood be Valuable in Identifying & Monitoring Patients With Post-proton Pump Inhibitor (PPI)-Responsive Heartburn PHASE1COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas PHASE1COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer EARLY_PHASE1COMPLETED
Foci of Tumor Heterogeneity in Diffuse Low-Grade Gliomas nanCOMPLETED
Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA nanRECRUITING
Profiling Gingival Crevicular Fluid β-Catenin Level With 8-OHdG and Total Antioxidants Capacity During Healing of Periodontal Pockets: A 3-month Clinical Trial nanNOT_YET_RECRUITING
The Activation of Hippo Pathway in Nasal Polyps nanUNKNOWN
Immune Cell Response to Stimuli nanRECRUITING
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study nanCOMPLETED
Biomarkers in Patients With Rhabdomyosarcoma nanCOMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer nanUNKNOWN
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia nanRECRUITING
Epithelial Mesenchymal Transition Markers in OSMF nanCOMPLETED
Evaluation of Lymph Node Analysis Using One Step Nucleic Acid Amplification (OSNA) in Patients With Lung Cancer Who Underwent Robotic Lung Resection, Comparison With Traditional Methods nanENROLLING_BY_INVITATION
Chilean Gastric Cancer Task Force (FORCE 1) nanCOMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
Epithelial Mesenchymal Transition and Periodontitis nanUNKNOWN
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis nanCOMPLETED
Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia nanCOMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
Prospective Monocentric Clinical-biological Database nanRECRUITING
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Influence of EMT on CTCs and Disease Progression in Prostate Cancer nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a EZR binder may also engage these)

ProteinNameSimilarity
P31977 1.000 P31977 →
P31976 1.000 P31976 →
P26040 1.000 P26040 →
Q8HZQ5 1.000 Q8HZQ5 →
Q7PS12 1.000 Q7PS12 →
P26043 1.000 P26043 →
P52962 1.000 P52962 →
P26044 1.000 P26044 →
P26042 0.999 P26042 →
O35763 0.999 O35763 →
P46150 0.999 P46150 →
P46662 0.998 P46662 →
Q2HJ49 0.998 Q2HJ49 →
P26041 0.998 P26041 →
Q32LP2 0.998 Q32LP2 →
RDX Radixin 0.998 landscape →
MSN Moesin 0.997 landscape →
Q9PU45 0.997 Q9PU45 →
Q66I42 0.996 Q66I42 →
Q63648 0.996 Q63648 →
Q170J7 0.996 Q170J7 →
Q29GR8 0.995 Q29GR8 →
B0WYY2 0.995 B0WYY2 →
P59750 0.992 P59750 →
P35240 0.992 P35240 →
Q24564 0.991 Q24564 →
Q6A028 0.986 Q6A028 →
Q7SYB5 0.984 Q7SYB5 →
PTK2 Focal adhesion kinase 1 0.983 landscape →
Q86T65 0.983 Q86T65 →